Kronox Lab Sciences Q1 FY27: PAT up 16% YoY to Rs 7.3 Cr as OPM eases to 31.7%
PAT +16.32% YoY · revenue +16.88% · margins flat
₹28.39 Cr
+16.88% YoY
₹7.3 Cr
+16.32% YoY
24.6%
-0.4pp YoY
₹2
Kronox Lab Sciences' standalone Q1 FY27 (quarter ended June 30, 2026) revenue came in at ₹28.39 Cr, up 16.9% YoY from ₹24.29 Cr and 8.6% QoQ from ₹26.13 Cr. PAT was ₹7.30 Cr, up 16.3% YoY from ₹6.28 Cr but down 8.7% QoQ from ₹8.00 Cr, with EPS at ₹2.0 versus ₹1.7 a year ago and ₹2.2 last quarter. Only a standalone statement was filed — the company reports a single reportable segment (high-purity specialty fine chemicals) under Ind AS-108, so there is no consolidated number to reconcile against.
Q1 FY-2027 vs prior quarters
Operating margin eased to 31.7% from 36.4% in Q4 FY26 and 32.8% in Q1 FY26, as other expenses rose to 12.25% of revenue (from 11.44% YoY) and the company carried a small finance cost (₹3.3 Lakh, versus nil a year ago) and higher depreciation (₹45.2 Lakh vs ₹40.1 Lakh), even as employee costs eased as a share of revenue (6.8% vs 7.35% YoY). Net margin held up better at 25.7%, roughly flat to slightly ahead of the 24.96% posted a year ago, helped by a similar effective tax rate (~25.6% of PBT) — but down sharply from 28.3% in the seasonally stronger Q4. The sequential PAT decline despite higher revenue points to the OPM compression, not a one-off, as the swing factor.
The stock went into the print at ₹173.93, up 18.8% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
There is no prior management guidance or concall commentary on record for this company, so the print cannot be benchmarked against a stated outlook — management gives no formal guidance. Analyst/street coverage on Kronox is thin; no consensus estimate for this quarter could be found, so the result cannot be graded against the Street either. No separate management press release accompanied the filing. Alongside results, the board approved book closure for a final dividend (record date September 9, 2026) and set the 17th AGM for September 16, 2026, plus routine re-appointments of internal and cost auditors — administrative items unrelated to the operating print.
W1
Whether OPM recovers toward the Q4 FY26 level of 36.4% or stabilizes near the 31–33% band seen in the last two quarters.
W2
Final dividend outcome at the Sept 16, 2026 AGM (record date Sept 9, 2026).
W3
Whether revenue growth (+16.9% YoY this quarter) holds given the company's single-segment concentration in specialty fine chemicals.
Only a standalone statement was filed (single reportable segment, no consolidated section); figures converted from Lakhs (÷100). Statement is unaudited but subject to statutory auditors' limited review (unmodified opinion). No exceptional items or minority interest.